PIK3CA and gastric cancer: In vitro we have shown that the PI3K inhibitor copanlisib and the MEK inhibitor refametinib have anti-proliferative effects as monotherapy in some HER2-positive GC cell lines, including those that are intrinsically resistant to trastuzumab.